Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
AstraZeneca
Baxter
McKesson
Johnson and Johnson

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

NITROPRESS Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Nitropress patents expire, and what generic alternatives are available?

Nitropress is a drug marketed by Abbott, Abbvie, and Hospira. and is included in four NDAs.

The generic ingredient in NITROPRESS is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.

US ANDA Litigation and Generic Entry Outlook for Nitropress

A generic version of NITROPRESS was launched as sodium nitroprusside by SAGENT PHARMS INC on December 13th, 2019.

Drug patent expirations by year for NITROPRESS
Drug Prices for NITROPRESS

See drug prices for NITROPRESS

Recent Clinical Trials for NITROPRESS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 2
American Heart AssociationPhase 2

See all NITROPRESS clinical trials

Pharmacology for NITROPRESS
Drug ClassVasodilator
Physiological EffectVasodilation

US Patents and Regulatory Information for NITROPRESS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott NITROPRESS sodium nitroprusside INJECTABLE;INJECTION 071555-001 Nov 16, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Hospira NITROPRESS sodium nitroprusside INJECTABLE;INJECTION 070566-001 Jun 9, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Abbvie NITROPRESS sodium nitroprusside INJECTABLE;INJECTION 018450-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Hospira NITROPRESS sodium nitroprusside INJECTABLE;INJECTION 071961-001 Aug 1, 1988 AP RX No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Merck
AstraZeneca
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.